Long-Term Tofersen Use May Slow ALS Progression, 3-Year Data Suggest

(MedPage Today) — Early initiation of tofersen (Qalsody) was associated with a numerically slower decline in people with SOD1 amyotrophic lateral sclerosis (ALS) compared with delayed treatment, according to data from the VALOR trial and its open…